This page summarizes what formal research has documented. It is not everything known about iboga: the Bwiti tradition and decades of clinical experience are knowledge too. Before you read: what science sees, and what it can’t.
Nobody yet knows exactly how ibogaine works. In laboratory and animal studies, ibogaine and noribogaine, the long-lasting substance the liver makes from it, act on many brain systems at once. The research in people is still small, so every finding here says whether it comes from people, animals or cells in a lab.
We provide ibogaine treatment, so we have a stake in how this research is read. If you’re here to decide about treatment, skip to what this means for you.
Which brain systems does ibogaine act on?
In lab tests, ibogaine and noribogaine bind to opioid receptors (kappa and mu), the NMDA glutamate receptor, the serotonin transporter and the α3β4 nicotinic receptor (Baumann et al. 2000). Binding in a lab is not the same as acting in a person.
For years, research in rats pointed mainly to the kappa-opioid and NMDA receptors. Later work in rats moved the emphasis to blocking the α3β4 nicotinic receptor in a small pathway from the habenula, which the 2026 MAPS Investigator’s Brochure presents as the core of the anti-addiction effect (Glick et al. 2002, lab cells and rats).
What is noribogaine, and why does it matter?
Noribogaine is the main substance the liver makes from ibogaine, mostly through an enzyme called CYP2D6. It stays much longer: its half-life is about one to two days, against several hours for ibogaine (Glue et al. 2016). It binds the serotonin transporter more tightly than ibogaine in lab tests, and it also affects heart rhythm. So it may carry part of the benefit, and part of the risk, after the experience has ended.
Is noribogaine an opioid? The evidence is disputed. A 1998 study in rat brain tissue found that it switched on the mu-opioid receptor; an independent team found that it weakly blocked it instead. Healthy volunteers given noribogaine showed no opioid-like signs. Noribogaine alone is not ibogaine treatment, and it is not a safer version of it.
What does ibogaine do to the brain after the experience ends?
Most of what is known comes from animals. In rats, ibogaine’s effect on alcohol drinking depended on GDNF, a growth factor that supports dopamine neurons, and a single dose changed GDNF and BDNF levels in dopamine-related regions.
In adult mice, one dose reopened a kind of plasticity in the visual cortex normally seen only in young animals. On its own, ibogaine did not change dendritic spines; they dropped only when one eye was also covered, the response normally seen in young animals: evidence of a reopened capacity to change, not of new connections growing (Acuña et al. 2026, in mice).
In people, brain data come from one small group. Thirty male veterans with traumatic brain injury received ibogaine with intravenous magnesium. One month later, their scores for disability, PTSD, depression and anxiety had improved by a large margin, and MRI showed a thicker cortex (MISTIC, Nature Medicine 2024, no control group).
Why does one dose seem to ease withdrawal and cravings?
Open studies report that most people show few signs of opioid withdrawal one to two days after a single dose, and that craving falls in the short term (no control group). Proposed reasons: noribogaine stays in the body for days, it acts on opioid and nicotinic receptors (seen in rats and lab cells), and growth factors and plasticity change for longer than the dose lasts (seen in rats and mice).
For many people, the early effect fades. In a study of 30 people treated in Mexico, half reported no opioid use one month later, and about one in four at twelve months (Brown & Alper 2018, self-reported, no control group). When use returns, which is common, it is not a personal failure.
The chemistry is only part of the work. During the retreat, our therapeutic team is with participants throughout, and the program includes two one-hour group sessions for preparation and integration.
How long does ibogaine stay in the body, and why do genes matter?
Ibogaine’s half-life is roughly 7 to 8 hours when CYP2D6 works normally. Noribogaine stays measurable for several days. CYP2D6 activity varies with genes and with other medicines: when healthy volunteers took paroxetine, which blocks CYP2D6, their combined exposure to ibogaine plus noribogaine roughly doubled (Glue et al. 2015b). In people with opioid use disorder, clearance varied widely with their CYP2D6 genes (Knuijver et al. 2024).
What this means if you’re considering treatment
Knowing how ibogaine acts in the brain does not make it safe. Both ibogaine and noribogaine lengthen the QTc interval on the ECG, and slower CYP2D6 activity raises exposure. Unsteadiness and tremor are common in the first hours.
Ibogaine can cause serious, sometimes fatal, heart rhythm problems; that is why everyone has an ECG before treatment. More in Ibogaine and the heart.
If you use opioids, this matters most: after treatment, tolerance to opioids may be lower, so a dose that used to be usual can cause a fatal overdose. Before you leave, we go over this with you in the departure assessment and give it to you in writing.
Ibogaine is not for everyone, and screening exists to find out. Before anyone arrives, we do a medical and psychological intake and review blood pressure, an EKG with the graph, a complete blood count, a basic metabolic panel, a urinalysis and liver function, all within three months of the retreat; a stress test may be required for people over 60 or with specific conditions.
We also review every medicine, supplement and herb you take, looking for anything that lengthens the QT interval, raises serotonin, interferes with CYP2D6 or lowers electrolytes. Strong CYP2D6 blockers, such as paroxetine, fluoxetine or bupropion, rule treatment out until they have been safely tapered and washed out. Antidepressants are tapered only with your own prescriber, and we schedule treatment once the washout is complete. Abnormal lab values are corrected before treatment, and everyone receives intravenous magnesium the day before the session.
Some substances, among them methadone, fentanyl, benzodiazepines, alcohol, kratom and some psychiatric medications, may need a taper or a supervised detox first, planned with our medical team. Please don’t stop or cut down anything on your own.
Our monthly retreat has two doses: the flood on Tuesday, which begins with a test dose so that slow metabolism shows itself early, and a booster on Friday. For someone known or suspected to be a slow metabolizer, we lower the dose. Participants stay in the team’s care through the whole retreat, and a physician gives medical clearance before anyone leaves. How medical screening and monitoring work walks through the process step by step.
Questions about whether this applies to you? Talk to our medical team. If you want to begin, start an application.
Frequently asked questions
Does ibogaine “reset” the brain?
That has not been shown in people. In mice, one dose reopened a youthful kind of plasticity; in people, the only brain data are MRI changes in one small group of veterans.
Is noribogaine an opioid?
The evidence is disputed. One rat study found that it switched on the mu-opioid receptor; an independent replication did not, and healthy volunteers given noribogaine showed no opioid-like signs.
Does ibogaine work like psilocybin or LSD?
Not in the same way. Ibogaine acts on many targets at once, and an early lab study found no affinity for serotonin 2 receptors. Researchers describe it as a “nonclassic” psychedelic.
Related topics
- What the research on ibogaine says
- Ibogaine and the heart
- How medical screening and monitoring work
- Research library
Medical note
Ibogaine is a Schedule I substance in the United States and is not approved by the FDA for any use. It carries cardiac risks and should only be taken under qualified medical supervision. This page is educational and does not replace a medical evaluation.
Reviewed by the IbogaQuest medical team · Last reviewed 10 October 2026
Sources
- Cherian et al. 2024 (MISTIC) · Nature Medicine · veterans with brain injury
- Brown & Alper 2018 · American Journal of Drug and Alcohol Abuse · opioid outcomes over twelve months
- Acuña et al. 2026 · BMC Neuroscience · plasticity in adult mice
- Glue et al. 2016 · Clinical Pharmacology in Drug Development · noribogaine in people coming off methadone
- Glue et al. 2015b · Journal of Clinical Pharmacology · CYP2D6 and ibogaine in healthy volunteers
- Knuijver et al. 2024 · Journal of Psychopharmacology · ibogaine in people with opioid use disorder
- Baumann et al. 2000 · Annals of the New York Academy of Sciences · receptor binding
- Glick et al. 2002 · European Journal of Pharmacology · α3β4 nicotinic receptors